Clinical trials: End of Life Care
Sudden Cardiac Arrest, Emergency Care
Tempus Pro Monitor Registry
A multicenter, prospective and retrospective, observational, post market study.
- Trial name
- NCT05587764
- Testing
- Standard of Care
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Heartstream US LLC
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Mitochondrial Diseases
EPI-743 for Mitochondrial Respiratory Chain Diseases
This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.
- Trial name
- NCT01370447
- Testing
- EPI-743
- Where
- 16 sites in United States
- Sponsor
- PTC Therapeutics
Medication Adherence, Satisfaction, Personal
Utilization of the TAD Device for Dispensing Pain Medications in Hospice Patients
A novel device, TAD, has been developed to aid adherence to prescribed regimens and may have a roll in hospice pain management. This study aims to assess medication adherence relating to missed doses or improperly timed doses…
- Trial name
- NCT03940534
- Testing
- TAD
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Intent Solutions, Inc.
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT05600309
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 24 sites in China
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Aging Problems
E-training of Inmate Peer Caregivers for Enhancing Geriatric and End-of-life Care in Prisons
The mission of corrections is to provide care, custody, and control for incarcerated individuals. United State prisons are required by constitutional law to provide adequate care for growing numbers of older inmates who will…
- Trial name
- P2P (NCT03323008)
- Testing
- Prototype
- Where
- 2 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer.
- Trial name
- NCT05064059
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 152 sites in United States, Australia and 19 more
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
End of Life Care
Behavioral Economics for Advance Care Options
People with life-limiting illness often receive more aggressive healthcare than desired including costly procedures that provide little medical benefit.
- Trial name
- BEACON (NCT02100566)
- Testing
- Counseling (Care giver burden focus), Counseling (patient autonomy focus)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Ascension Health
Respiratory Disease, Cardiovascular Diseases
Hospice Quality Score Assessment Post Pharmacist Intervention
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.
- Conditions
- Respiratory Disease, Cardiovascular Diseases, Neurologic Disorder, Dementia
- Trial name
- NCT04361669
- Testing
- Medication safety review
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06445972
- Testing
- Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan
- Where
- 46 sites in United States, Brazil and 9 more
- Volunteers
- 210 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult…
- Trial name
- ARTEMIDE-subQ (NCT07161414)
- Testing
- IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig
- Where
- 11 sites in United States, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
The purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer.
- Trial name
- NCT04776148
- Testing
- pembrolizumab, lenvatinib, regorafenib
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 563 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 191 sites in United States, Argentina and 27 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC